What is CRIS's P/E ratio?

CURIS INC (CRIS) currently trades at a P/E ratio of 1.01.

CURIS INC reports a Return on Equity (ROE) of -166.56%.

What is CRIS's dividend yield?

CURIS INC offers a dividend yield of 0.00%.

What is CRIS's Deepscope Quality Score?

Deepscope rates CRIS's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy CRIS?

Deepscope's AI Timing Score for CRIS is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does CRIS belong to?

CURIS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

CRIS (NASDAQ) 株価分析 | CURIS INC

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-05 | FS: 2026-03-31)

CRIS

CURIS INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 95

USD 0.47

-0.03 (-5.34%) Day Change

Watchlist Portfolio Compare Chart

1.01

P/E

0.10

D/E

-166.6%

ROE

-71.3%

ROA

0.00%

Div Yield

-0.02

PEG

CURIS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 0.47 Price -0.03 (-5.34%) Day Change	NEWS SCORE: 95

CRIS, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...

Deepscope 分析

47%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	95
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	0.47
PBV / Sector	1.53 / 4.63 GOOD
Earning Per Share	-0.51

PE / Sector	1.01 / 17.43 GREAT
PEG or PE/Growth / Sector	-0.02 / 0.53
Average 1M Daily Value	0.11 M GREAT
Average 1W Daily Value	0.10 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

62%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-299.66 / 449.48
NPM Average (%) / Sector	-368.88 / -1,506.49
NPM Change Average (%) / Sector	39.29 / 4,940.99 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-71.30 / 30.58
ROA Average (%) / Sector	-66.24 / -347.17
ROA Change Average (%) / Sector	26.49 / 5,125.52 GREAT
ROE (%) / Sector	-166.56 / -3.58
ROE Average (%) / Sector	9.48 / 40.65
ROE Change Average (%) / Sector	-103.32 / 2,109.80
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 4.17

登録情報

Analyze Date	2026-06-06 09:08:21
Symbol	CRIS
Name	CURIS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	38.98 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	19.49 / 8,857.28

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Building C, Lexington, MA, United States, 02421

Phone: 617 503 6500

Website: https://www.curis.com

Sector: Healthcare >> Biotechnology

Description: Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.